The one-sentence version

German regulators and German pharmaceutical lawyers now have a name for what most exporters do: GMP-washing, applying EU-GMP process steps after harvest to make GACP-grown flower look compliant. It has a legal basis that predates the current debate by 17 years, and authorities are enforcing it.

The legal basis is older than you think

This isn’t a new interpretation invented in Hesse this June. The German Federal Ministry of Health defined the GACP/GMP boundary in an official 2009 annex, classifying which processing activities fall under GACP, under Part II of the EU-GMP Guide, or under Part I. Cutting and drying of plant material sits explicitly in the GMP-classified zone, not the agricultural one.

The WHO’s own GACP guideline, from 2003, is the source of the loophole everyone has been using: it permits initial drying “in the field under appropriate conditions, such as sun drying or shade drying.” That sentence is doing a lot of work in the industry’s compliance memos. German regulators read it narrowly, appropriate initial drying only, not the drying that determines whether the batch is safe to release.

BfArM made the practical consequence explicit in 2023: a GMP certificate must be submitted for each company involved in the drying step. Not each company involved in cultivation. Each company involved in drying, specifically. If your farm dries and your buyer’s EU facility only finishes, packages, and tests your farm is the company that needed the certificate, and it doesn’t have one.

What Section 72a AMG actually requires

For flower to enter the German market, the Pharmaceuticals Act requires, cumulatively:

• EU-GMP compliance for all relevant manufacturing steps
• A valid GMP certificate from a competent EU authority (or one recognised as equivalent) — and it must cover the exact site and the exact processes used, not a general certification of the company
• Confirmation by a Qualified Person
• An import licence under Section 72 AMG
• Full batch traceability, including GACP evidence for cultivation and separate GMP documentation for every post-harvest step
• Compliance with the German Pharmacopoeia (DAB/Ph. Eur.)

Some authorities read this strictly: every imported flower must have been processed under EU-GMP conditions before it enters the German market. Under that reading, a certificate issued to your EU-side processor does not retroactively cover what happened at your farm.

Why a clean lab result won’t save you

This is the argument every exporter reaches for, and it’s the one German pharmaceutical lawyers explicitly reject. A Certificate of Analysis reflects the sample tested — not the batch, and not the process that produced it. EU pharmaceutical law is process-based, not test-based. If a critical step wasn’t performed under GMP, the product is not legally compliant even if the COA is spotless. And some defects, contamination introduced during an uncontrolled multi-week transport, for instance, cannot be corrected by irradiation or after-the-fact testing. Irradiation kills organisms; it doesn’t undo the regulatory fact that an unvalidated process produced the batch.

Why the enforcement climate is tightening now

Four converging pressures, according to German life sciences counsel:

1. A live case. Portugal in 2025 saw enforcement action attributed directly to this issue. Pharmaceutical lawyers are now citing it as a precedent when advising clients.
2. A rising rate of quality-related findings in the flower supply chain generally.
3. Political pressure, the same climate that produced the GKV-Beitragsstabilisierungsgesetz and the MedCanG-Novelle is pushing regulators to close gaps rather than tolerate them.
4. Canadian producers are struggling to obtain EU-GMP certificates at all: A signal that the bar for the underlying certification, not just its application to drying, is rising across the board.

What happens if you’re found out

Discovery of GMP-washing is not a paperwork correction. The consequences named by counsel: inspections, Corrective and Preventive Action requirements, suspension of certificates, import stops, and recalls. A recall on a pharmaceutical product reaches every downstream pharmacy and patient record it touched. This is not contained to the shipment in question.

Where the genuine grey zones are and how narrow they are

Whole-plant pre-drying (Saxony-Anhalt). Permitted for the whole plant, not for already-separated flower, subject to case-by-case review. Trim-at-origin – the standard model – falls outside this.

Isolated statements about short-term transitional arrangements at individual district authorities are not consistently documented and are deliberately not treated here as a reliable grey zone. Confirm any case-by-case allowance directly with the competent authority and your own Qualified Person before building a sourcing model on it.

Do not build on the map

Several German states have not published a position. Not one that has responded has contradicted the strict reading. Structuring your import model around a jurisdiction’s silence, or around the state that left the most room, is a bet that the authority and the Qualified Person who signs off and carries personal liability, will take the permissive reading. Increasingly, they aren’t.

What to do

This month

1. Draw the process flow. Per batch: which step, which site, which supplier, which standard. German applications now require this, and it’s also your own evidence that you understand where your GACP/GMP boundary actually sits.
2. Locate that boundary honestly. If it falls after drying, this is not a documentation gap. It’s the core of your compliance exposure.
3. Tell your German customers before they find out themselves. Importers and QPs are re-screening supplier bases. Disclosure keeps you in the conversation; discovery ends it and can trigger a recall that damages the relationship permanently.

This quarter

4. Move drying and trimming inside the GMP boundary, at origin. Qualified drying rooms, environmental monitoring, validated drying profiles with defined endpoints, GMP documentation from the moment of harvest.
5. Re-scope your GMP certification so it explicitly covers the cultivation-site drying step, not just downstream processing.
6. Ask your QP directly how they read Section 72a AMG on this point, and get it in writing before you sign anything.

Strategically

7. Reprice the model honestly. GMP drying at origin is capital expenditure: HVAC, monitoring, qualification, documentation, trained personnel. Model it before deciding whether Germany remains viable for you.
8. Turn compliance into positioning. Years of price pressure rewarded exactly the practice now being named and enforced. A shrinking pool of suppliers can genuinely deliver compliant product. Early movers become the scarce input.

The honest bottom line

This has moved past a documentation exercise. German pharmaceutical lawyers now use “GMP-washing” as a defined term of art, tie it to a specific 2009 legal basis, and describe named enforcement consequences, not hypothetical ones. The producers who invest in GMP-qualified drying at origin in 2026 will be supplying Germany in 2028. The ones waiting for the interpretation to soften will be explaining to their investors, and possibly to a regulator, why their EU pipeline disappeared.

A note on sourcing: The state-by-state authority positions cited in this report come from a survey conducted by Krautinvest, which contacted every German state authority individually and published the responses in full — a service the industry didn’t have before and one worth crediting directly: Medizinische Cannabisblüten: Was die zuständigen Behörden von einer Vortrocknung unter GACP halten, Krautinvest, 17 July 2026.

This briefing is a business analysis, not legal advice. Case-by-case review requires qualified legal counsel.